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We have constructed a formal model on cost-beneﬁt of new technology in health care, and apply it on
boron neutron capture therapy (BNCT). We assume that the patient health beneﬁt from getting cured in
acute treatment is always higher than the patient utility resulting from any long term treatment or death.
This assumption makes it possible to evaluate the monetary cost impacts of a new technology and relate
these measures to the patient health beneﬁt.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The health care sector has reached a major crossroads in many
Western countries. Particularly, advances in medical science, rising
pressures from a growing elderly population and the discovery of
previously unknown disease mechanisms bring with them new
and more effective treatments causing rapidly increasing cost
pressures. Hence a vast amount of Health Technology Assessment
(HTA) in general and cost-beneﬁt analyses in particular have been
performed, and they are also a central issue in any discussions of
future health care.2. Measuring health beneﬁts
The concept of Quality-Adjusted Life-Years (QALYs) has becomer Ltd. This is an open access article
te of the Finnish Economy,the most commonly used method to measure health beneﬁts in
health economic evaluations (Blomqvist, 2002; Dranove, 2003; Ba-
ker et al., 2005; Dolan et al., 2005). For example, the National In-
stitute for Clinical Excellence (NICE), in the UK, uses QALYs in cost-
utility analyses of health technologies. The method has been com-
pared with the basic Cost-Beneﬁt Analysis (Bateman et al., 2003;
Dolan et al., 2005; Phelps and Mushlin, 1991; Johannesson, 1995;
Garber and Phelps, 1997; Bleichrodt and Quiggin, 1999; Dolan and
Edlin, 2002).
The notion of a QALY itself has been critically evaluated, but the
greatest concerns have been around the assumption of linearity of
the model and the correctness of the social dimensions of a QALY. A
QALY is sensitive to the valuation method used, such as time trade-
off and standard gamble, as well as the study set-ups (e.g. Cook et al.
(2001), Richardson et al. (1996), Bleichrodt and Johannesson (1997),
Treadwell (1998), Treadwell et al. (2000), Bala et al. (1999), Unic
et al. (1998), Sackett and Torrance (1978), McNeil et al. (1981),
Miyamoto and Eraker (1988), Stalmeier et al. (1997) and Jo-
hannesson and Johansson (1997)). Moreover, a QALY has been
claimed to introduce values into the monetary calculations in a
manner that does not show robustness or which might notunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Harris (1991), Dolan (1998), Nord (1993), Ubel et al. (1999), Cookson
and Dolan (1999), Ubel et al. (1999), Hadorn (1991), Shmueli (1999),
Anand and Wailoo (2000), Choudhry et al. (1997), Olsen
(2000), Rodriguez-Miguez and Pinto-Prades (2002), Ubel et al.
(2001), Beresniak et al. (2010) and ECHOUTCOME (2013)). For a
further discussion, see Dolan et al. (2005) and Blomqvist (2002),
with references therein.
Willingness to pay (WTP) has more recently been used in
conjunction with QALYs in assessing net beneﬁts of medical in-
terventions (Berg et al., 2007; Borgstrom et al., 2006; Deutsch
et al., 2006; Fox et al., 2007; Hurley et al., 2007; Lyman et al., 2007;
Quigley et al., 2008; Remak et al., 2005; Rubenstein and Inadomi,
2006; Rutten-van Molken et al., 2007; Steuten et al., 2007;
Thompson Coon et al., 2007). However, critical concerns have been
raised both concerning the validity of WTP for a QALY, and the use
of QALYs per se. Empirical estimates of WTP for each QALY have
yielded results ranging from 0.20 NOK (€0.03) to US$49,133
(€31,186) (Cunningham and Hunt, 2000; Blumenschein and Jo-
hannesson, 1998; Zethraeus, 1998; Bala et al., 1998; Olsen and
Donaldson, 1998). Such a large range of values understandably
casts doubt on the validity of this methodology. For further dis-
cussions on using WTP for QALY, see Baker et al. (2005) and
Blomqvist (2002), with references therein.1 From an operational point of view, slackness should always be minimised as
long as it incurs cost savings. In health care, there is a necessary conﬂict between
redundancy (also called excess capacity) and operational efﬁciency: redundancy is
desirable for public health reasons, such as potential widespread acts of terrorism,
natural disasters and pandemics. If a provider unit is running optimally in an
economic sense, however, it does not include redundancy. The model is designed to
accommodate redundancy that can be included in a ﬁnancial surplus S, but in this
empirical case additional surplus is set at zero as it is already part of the costs
derived from the hospitals' price lists.3. A cost-beneﬁt model for new technology
While there are many cost-beneﬁt studies in the health eco-
nomics literature, measures do not usually formally assess the
social or economic optima of acute intervention versus long term
treatment. To ﬁll this gap we have developed a formal model that
includes the entire treatment chain, and apply it on BNCT tech-
nology in brain tumour treatment.
The model can be used both for descriptive and normative
analysis. We obtain predictions for the observed behaviour in the
real world, and normative recommendations for the choice of
technology. While current literature predicts hospitals to continue
their current behaviour, normative analysis suggests that such
behaviour may, in fact, be inefﬁcient. This inefﬁciency is due to
costs and beneﬁts of the long term care.
In this article we introduce an innovative theoretical model
with which a new technology can be applied to an acute inter-
vention. This application, in turn, affects the number of patients
requiring long term treatment. The aim of the formal theoretical
model is to show how the patient health beneﬁt and monetary
costs obtained from the adoption of new technology in the acute-
care intervention can be related to those of the long term treat-
ment. For this article we deﬁne long term treatment as the need
for prolonged use of medical products (such as pharmaceuticals
and devices), medical services as well as required social services
(such as home or institutional care) after the acute intervention.
Following the discussion by Buxton et al. (1997), we con-
structed a model that
1. is as simple as possible,
2. is as transparent as possible,
3. is possible to generalise to several setups,
4. offers an adequate comparison with current treatment(s),
5. respects the quality of the data in the model, especially helping
the reader to distinguish between hard data (e.g. collected
through controlled studies) and soft data (e.g. obtained from
expert opinion), and
6. allows the assessment of robustness with appropriate sensitiv-
ity testing.A description of the model and an example of applying it on
thrombolytic therapy for stroke is downloadable from http://
www.etla.ﬁ/julkaisut/dp1037-ﬁ/, and a free and non-proprietary
version of the model transferred into a fully functional calculation
engine at www.etla.ﬁ/cost-beneﬁt, to which home pages also
further cases will be added. In this paper we will only show the
input parameters and the end results of the formal modelling.
3.1. Input parameters
The formal model uses following inputs
Acute care and long term care
Technologies 0, 1 and 2 (t0, t1, t2)
Respective prices for each technology (p0, p1, p2)
Severity of disease: high or low severity (h, l)
Functional capacity of patient d
Probability of low severity after treatment τt¼Prob(d¼ l|t)
Number of patients (n)
total cost of applying technology t to n patients npt
Fixed costs F
Treatment intensity (q)
Budget and budget share allocation (mB)
Slackness and Financial Surplus (S)
Cost functions for acute and long term treatments (C and c)
Patients' utility or health beneﬁt scores from having a low
functional capacity (ul, u 0l ≥ ) or being only mildly ill (uh, u uh l> )
after acute-care intervention, and a beneﬁt v(q) of treatment in-
tensity q from the long term treatment.
Assumption: zero proﬁt constraint1
Acute intervention refers to furnishing the initial treatment for
patients.
3.2. Key results on efﬁcient technology and treatment
A socially optimal technology and treatment intensity t q,( * *)
maximises the per-patient net beneﬁt. Socially optimal treatment
intensity equates the patient-level marginal beneﬁt with marginal
cost. Solving for the general model yields that a socially optimal
acute-care intervention technology t satisﬁes the condition
u u v q p c q
u u v q p c q
1 1
1 1 3.1
t h t l t t
s h s l s s
τ τ τ
τ τ τ
+ ( − )[ + ( *)] − − ( − ) ( *)
≥ + ( − )[ + ( *)] − − ( − ) ( *) ( )
Modifying the inequality (3.2) we obtain
u p p V q c q 3.2t s t s t sτ τ τ τ( − )Δ ≥ − + ( − )[ ( ) − ( *)] ( )
where u u uh l− = Δ and v q V q( *) = ( ). If technology t is more ef-
fective than technology s, the condition (3.2) can be rewritten as
u v q
p p
c q ,
3.3
t s
t sτ τ
Δ − ( *) ≥
−
−
− ( *)
( )
and, if technology s is more effective than technology t, the con-
dition (3.2) can be rewritten as:
u V q
p p
c q .
3.4
t s
t sτ τ
Δ − ( ) ≤
−
−
− ( *)
( )
Table 1
The parameters for glioblastoma multiforme.
Glioblastoma Multiforme
Functional capacity d h (high) l (low)
Obtained utility v(q)
corresponding to Karnofsky Z70 o70
Health care budget B 4.440 mill
0 40
Technology t t0 t1 t2
Patients N 150 150 150
Price of technology (total) p 0 363,000 890,120
probability of having a low severity of
disease
τ 0 0.082 0.123
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can be explained as
Cost per cured patient¼ c qpt
t
− ( )τ , where
 cost of one treated patient is divided by effectiveness; this re-
sults in how much one successful treatment costs, and
 long term treatment cost is subtracted from this cost, as a cured
patient does not need long term treatment.
The result can also be negative, meaning that using the acute
intervention actually saves money.
The left-hand sides of the inequalities (3.3) and (3.4) can be
interpreted as willingness to pay for health improvement from ul
to uh. Average cost of treatment c(q) 27,1824. Applying the model on boron neutron capture therapy
Glioblastoma multiforme has eluded efﬁcient therapy, with the
most effective treatment offering only a 15 month extension of life
after diagnosis. (Andersen, 1978; Chin et al., 1981; Kristiansen
et al., 1981; Lacroix et al., 2001; Stupp et al., 2009, 2005; Walker
et al., 1978, 1980). In this section we deﬁne the Finnish Boron
Neutron Capture Therapy (BNCT) project as technology 2. BNCT is
an expensive radiation treatment with high startup and ﬁxed costs
(for a detailed explanation see (Joensuu et al., 2003) and refer-
ences therein).2
4.1. Deﬁning the parameters for glioblastoma treatments
The parameters for glioblastoma multiforme are collected in
Table 1.
The regulator is the Hospital District of Helsinki and Uusimaa,
HUS. However, there will still be only one BNCT treatment station
in the foreseeable future, and as glioblastomas are rare, our im-
plementation will cover entire Finland.
The acute intervention is provided by the Departments of
Neurology, Neurosurgery and Oncology at HUCH, serving under
HUS. The acute phase is here deﬁned to include direct costs that
are additional to normal treatment costs for patients suffering
from glioblastoma multiforme.
The long term treatment is provided by HUCH and the regional
hospitals of Helsinki and Uusimaa, all serving under HUS. In con-
trast to stroke, the majority of long term treatment is delivered
during the ﬁrst year from diagnosis.
The number of patients is approximately 150 per annum (Oh-
gaki and Kleihues, 2005).
Severity of illness at referral to the acute intervention provider
is deﬁned as glioblastoma with clear symptoms of disease and a
Karnofsky score below 70; the Karnofsky score will be discussed in
more detail below.
Technology 0, t0, consists of prompt diagnosis, acute interven-
tion, a neurosurgical operation and supportive care given initially
at HUCH and later mainly at the regional hospitals. We deﬁne this
technology as baseline treatment incurring no additional costs;
thus p0¼0.
If the patient does not present with speciﬁc contraindications,
she is usually offered radiation after the neurosurgical debulking.
Concurrent temozololamide and radiotherapy followed by2 BNCT was originally developed solely for treating glioblastoma mutliforme,
but later successfully developed to treat head and neck cancer. In this paper we use
the data from the test treatments for glioblastoma multiforme in Finland as our
example, as that was the original issue decision makers faced when considering the
introduction of BNCT into Finland. In 2005 the glioblastoma treatments were at
their peak, so we will use year 2005 as our reference point for costs.adjuvant temozololamide is the present established care with a
more than doubling of 2-year survival rates compared to radiation
only (Stupp et al., 2002, 2009, 2005; Yung et al., 2000). Moreover,
a multitude of other treatment modalities are being developed and
assessed, such as new operative techniques, advances in radio-
therapy, new combinations of chemotherapy, biological response
modiﬁers, and gene therapy (Anton et al., 2012).
We deﬁne Technology 1 as consisting of: (1.) a neurosurgical
operation with the aim of removing all malignant tissue, and (2.) a
full series of traditional radiation therapy sessions, in addition to
normal supportive procedures and therapy.
Of these two treatments, only the radiation therapy incurs
additional cost when compared to technology 0. As the equipment
is used mainly for the treatment of other, more frequently occur-
ring, diseases, we do not accrue initial ﬁxed costs for the in-
troduction of technology 1; the ﬁxed costs are adequately included
in the DRG price for glioblastoma multiforme, and hence p1¼2,420
€/patient3 (Neurology, 2005; Neurosurgery, 2005; Oncology
knowledge centre Hospital District of Helsinki and Uusimaa HUS,
2005). As an intensiﬁed acute treatment leads to a longer survival
time, we assume that the DRG price adequately reﬂects the true
total additional costs induced by technology 1.
Technology 2 encompasses: (1.) a normal neurosurgical opera-
tion, followed by (2.) BNCT-treatment.
The additional costs induced by technology 2 consist of allo-
cated ﬁxed and variable costs associated with BNCT therapy, less
the price for giving a full series of conventional radiotherapy
(which BNCT replaces). As several other brain cancer treatment
modalities are being actively developed, especially accelerator-
based neutron sources, we assume that the effective life cycle for
nuclear reactor based BNCT is 10 years, after which the technology
will become too obsolete to be competitive (Blue and Yanch, 2003;
Kononov et al., 2004; Lee et al., 2004; Svensson and Moller, 2003).
The ﬁrst patient in Finland was treated on May 1999, and by May
2005 a total of 42 brain tumour patients received BNCT treatment
(Kankaanranta, 2005, 2011c). Projecting a steadily rising patient
stream, we for demonstration purposes assume 100 more patients
would have been treated during the following four years. We ad-
ditionally assume that the increasing patient stream brings about
savings due to a streamlining of the procedures, which compen-
sates for the impact of inﬂation on costs. Keeping the price for one
treatment at the 2005 level, i.e., 20,000€, we obtain a price for
technology 2: p2¼890,120€.43 Corresponding to a total cost of p1tot¼(2,420€/patient*150 patients)¼
363,000€.
4 The cost for introducing technology 2 is p2¼(2420€/patient*136 patients
[treated conventionally]/year)þ2,000,000€/10 yearsþ20,000€/patient*14.2 pa-
tients/year¼329,120þ200,000þ280,000€¼890,120€.
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councils; however, in the case of rare diseases with interventions
centralized to university hospitals, the budget is set by the re-
spective university hospitals. As BNCT is given solely at HUCH, the
decisions are made by a political council with representatives from
all communities in Helsinki and Uusimaa that refers patients to HUS.
We approximate the total budget for treatment of glioblastoma
multiforme in Finland to be 4.440 million€ annually (City of Hel-
sinki, 2005a, 2005b, 2005c; Neurological department Hospital Dis-
trict of Helsinki and Uusimaa HUS 2005; Neurology, 2005; Neuro-
surgery, 2005; Neurosurgical department Hospital District of Hel-
sinki and Uusimaa HUS 2005; Oncology knowledge centre Hospital
District of Helsinki and Uusimaa HUS, 2005).5
The share of budget allocation to acute intervention Ba is also in
brain tumour treatment set by HUS. However, in contrast to
treatment of stroke, only the initial costs of introducing technol-
ogy 1 were born by the acute intervention. The establishment of
the BNCT treatment station was strongly supported by the Na-
tional Technology Agency of Finland and therefore HUCH incurred
no additional costs. Our model intends, however, to take as broad a
view as possible, and thus we also include the ﬁxed costs for
technology 2 into the calculations.
The obtained utilities ul and uh are deﬁned as the end-points of
low and high functional capacity, corresponding to high and low
severity of disease, respectively. The Karnofsky Performance Scale
combines the degree of disease with a person's ability to care for self
(Karnofsky et al., 1948). While it is widely used, it offers only a rather
arbitrary assessment of severity of disease (Green, 1997; Murray
et al., 1995; Slevin et al., 1988). However, since it has been commonly
used in clinical trials concerning brain tumour treatment, we use it
for the purpose of this study. Consequently, we deﬁne a Karnofsky
score of Z70 (70¼cares for self, unable to perform normal activity
or to do active work) as demonstrating low severity of disease; high
severity is deﬁned as a Karnofsky score of o70.
The obtained health beneﬁt is evaluated at one year after di-
agnosis as a function of the end-point and the probability tτ of
achieving that end-point.
At the end of the acute intervention phase, we deﬁne a patient
with a Karnofsky score of Z70 as experiencing a positive health
beneﬁt from the treatment uh40; even if the patient started with a
score 470, the treatment can prevent deterioration. On the other
hand, if the Karnofsky remains below 70, the health beneﬁt: ull¼0.
Surplus S stems from an uneven allocation of resources, and
thus S is preferably minimised. This assumption holds with all
units in HUS.
The enhanced probability of having a high functional ability
after basic treatment, i.e., a Karnofsky score of Z70 at one year
after diagnosis, is 0 for technology 0 ( 00τ = ), 0.082 for technology
1 ( 1τ ¼ 0.082) (Kristiansen et al., 1981; Laperriere et al., 2002).6 For
BNCT, the developers strived for an enhancement of τ by 50%,7
yielding 0.1232τ = (Kallio et al., 1997).
We derived the average cost c(q) of treating one Finnish glio-
blastoma patient with reference technology 0 (p0) by combining
several data sources.8 The reference technology yields a total5 This budget consists of initial treatment costs of (2,400€þ7,020€þ2,420€)¼
11,840/patient (diagnosis, initial treatment, neurosurgery and radiation therapy)
and a three month late stage period totalling 16,200€, where the patient is again in
need of intensiﬁed support and treatment.
6
1τ was derived by combining: (1.) Performance data on glioblastoma patients
after operation and radiotherapy with or without chemotherapy, yielding an
average 62% of patients not capable of caring for self at one year, and (2.) Risk ratio
for 1-year mortality of post-operative radiotherapy versus no radiotherapy ¼0.81.
7 The enhancement reﬂected anticipations of both a better survival for a sub-
population as well as a better quality of life as assessed by ability of caring for self.
8 The DRG price 2,420€/patient reﬂects costs accrued from initial diagnosis and
treatment (HUS 2005a). The initial CT-scan has to be complemented by an MR-average cost 27,182€/patient.
4.2. Results
As indicated earlier, the utilisation of BNCT on glioblastoma-
type brain cancer demonstrates a rather different setup for as-
sessing the adoption of a new technology in health care. In e.g.
thrombolytic therapy for stroke the key elements are an efﬁcient
treatment chain (availability) and marginal costs, whereas for
glioblastoma multiforme the ﬁxed costs and recovery rates prove to
be critical.
In economic terms, BNCT seems to be the opposite of e.g.
thrombolysis in stroke, where introduction of thrombolytic ther-
apy induces a negative cost on healthcare – in other words, it saves
money. For BNCT our model suggests that the health care payer
decides to adopt the BNCT technology in acute intervention if the
added value (or opportunity cost) of a successful acute treatment
compared to optimal long term care exceeds 58,528€
u v q 58, 528€ 4.1Δ − ( *) ≥ ( )
Technology 2 does not offer any direct economic advantage,
and thus the choice between technologies is uncertain. BNCT was
originally developed for treating glioblastoma mutliforme; at
present focus is particularly on treating severe forms of head and
neck cancer (Kankaanranta et al., 2011b). In this paper we use the
data from the treatments for glioblastoma multiforme in Finland
as our example, since that data is available together with pub-
lished full cost data for the preferred main treatment (radiation
therapy) of the same period.
In retrospect, we are aware of the technology being adopted,
but the not-for-proﬁt treatment company went bankruptcy in
2012. However, a similar cost beneﬁt analysis for BNCT treatment
of head and neck cancer as well as a comparison with radiotherapy
combined with temozololamide would be logical next steps of
research.
4.3. Sensitivity analysis – one way of looking into the future
The introduction of technology 2 (BNCT) is associated with high
startup costs. Typically they consist of building a treatment facility
by remodelling an existent reactor or acquiring an accelerator
based system; for the Finnish BNCT station the calculated initial
investment was 2M€. Such costs could be recovered either by
enhancing the patient base and thereby a higher number of
treatments in a single unit, or by introducing a new technology
which has higher direct health beneﬁts and/or a lower variable
cost.
A sensitivity analysis shows, however, that with the sunk costs
that high, the cost-efﬁciency frontier for technology 2 does not
break zero for any patient number (Fig. 1). As shown in Fig. 2, re-
applying the model, while varying the recovery rate τ, demon-
strates that the costs of technology 2 quickly diminish with an
increasing recovery rate. BNCT in Finland was developed further to
treat malignant cancers of the head and neck region – indeed with
even signiﬁcantly higher recovery rates (Kankaanranta et al.,(footnote continued)
imaging and followed by neurosurgery, adding up to a total cost of 7,020€ (HUS
2005b). We exclude costs related to radiation therapy. With such treatment, the
weighted average median survival of patients is 18 weeks, with an initial im-
provement phase, a long phase of deterioration and concomitantly an increasing
need of care with occasional visits to an acute intervention unit (Chin et al. 1981).
The supportive phase is about two thirds of the total survival time (Kristiansen
et al. 1981), and thus we approximate the average price of later stage treatment to
17,762€ (City of Helsinki 2005a, 2005b, 2005c). The average treatment duration is
83 days and the daily cost 214€.
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Finally, the impact of varying the prices for technologies 1 and
2 is shown in Fig. 3. Since variable costs, by deﬁnition do not
change with volume, Fig. 3 could be seen as reﬂecting differences
in, e.g., prices of available accelerator solutions and thereby dif-
ferences in pricing of offered treatment.
The model suggests that technology 2 is not economically
competitive with present recovery rates; however, it can be cho-
sen on other grounds. Such arguments could be: an interest in the
technology per se, a vision of a development of the technology to
become more competitive, or a lower risk of death or dependency.5. Conclusions and discussion
BNCT for glioblastoma multiforme presents a rare disease with a
low probability of recovery, high sunk costs as well as acute
treatment costs but relatively low long term treatment costs due
to the rapidly aggressive progression of the disease. A new tech-
nology showing low effect but high initial costs calls for a larger
population base that would only be possible with international
cooperation. Yet, the rationale for adopting the technology must
be found from other sources than pure economic reasoning.
The beneﬁts from an adoption of new technology can be purely
humanitarian, or they might involve economic impacts, typically
secondary and indirect, that have not been taken into account in
the conventional cost-beneﬁt calculations. Examples of potentialbeneﬁts are
1. the non-monetary value of avoiding deaths per se,
2. the non-monetary value of an early recovery, leading to a better
quality of life,
3. a preponderance of new technology per se,
4. spillover effects from supporting a novel technology (e.g. appli-
cations in other ﬁelds or further applications in the same ﬁeld).
The above beneﬁts are difﬁcult to measure in monetary terms.
The main beneﬁt of the model is that it enables the comparison
between the non-monetary health beneﬁt and monetary cost-ef-
fectiveness. Although this presentation enables a direct valuation
of distinctive policy decisions, it does not provide strict answers
about whether the payer should adopt the new technology.
Developers of new technology can use this model to assess the
impacts of their innovations, thereby supporting their [clinical]
testing approval and pricing strategy. Similarly, the model func-
tions as a means of transparent assessment and communication,
for example between a company or research entity and the gov-
ernment agencies responsible for supporting, evaluating and im-
plementing technological developments.
Finally, we need to recognise that any new technology can in-
itially be regarded as overly expensive. But we also need to re-
cognise, that almost by deﬁnition technologies develop and be-
come not only cheaper but also more efﬁcient. This indeed is very
true also with BNCT: malignant glioma treatments were followed
by more successful head and neck treatments, novel carriers are
approaching clinical trials, and the era of accelerator based neu-
tron beams has just begun. We encourage the use of our model's
sensitivity analysis charts to analyse as well as communicate what
happens, when parameters change.
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